The ambition is real, but "end the way drugs have been developed" is doing a lot of work in that sentence, and the part that gets glossed over is where computational prediction meets biological reality.
AlphaFold predicting protein structure was genuinely revolutionary. But structure is one layer. A drug candidate still has to navigate absorption, distribution across tissues, metabolism by liver enzymes, and elimination, and those dynamics are governed by differential equations that are exquisitely sensitive to biological variability between patients. The math exists. The models exist. What resists clean prediction is the probabilistic noise in living systems, which is something I worked through in some depth at
onhealthcare.tech/p/mathemat… when looking at how pharmacokinetics modeling keeps running into the same wall: biology doesn't hold still the way a physics equation expects it to.
Isomorphic Labs is collapsing one genuinely hard problem, which is molecular fit. The harder problem downstream, clinical translation, toxicity in heterogeneous populations, emergent off-target effects, remains stubbornly wet and biological in ways that no protein structure database fully captures.
The project deserves the attention. The framing of it as an ending rather than a significant acceleration of one specific phase probably needs complicating.
Demis Hassabis, the Nobel Prize winner who runs Google DeepMind just described the most consequential project on earth, and most people have no idea it exists.
The project is called Isomorphic Labs and the goal is to end the way drugs have been developed for the last century.
Here is the problem it is trying to solve.
Developing a single drug today takes an average of 10 years, costs billions of dollars, and fails 90 percent of the time before it ever reaches a patient.
Of every 10 drugs that enter clinical trials, only one makes it through.
The other nine years of work, the other billions of dollars, the other scientific careers, gone.
Hassabis believes AI can collapse that entire process from identifying a disease target to designing a compound that binds to it, predicts how it behaves in the body, and minimizes side effects , end to end, on a computer, before a single experiment is run.
The foundation is AlphaFold, the AI system that solved one of biology's hardest problems predicting the 3D structure of every protein in the human body and won him the Nobel Prize in Chemistry in 2024.
But knowing a protein's shape is only one part of designing a drug.
Isomorphic is building what Hassabis describes as adjacent systems , AlphaFold 3, AlphaFold 4, and now a unified model called IsoDDE , that take the next steps.
From designing the actual chemical compound that binds to the protein, predicting its binding strength, identifying new pockets to target that no one has ever found before.
IsoDDE more than doubles the accuracy of AlphaFold 3 on the hardest protein-ligand prediction benchmarks that exist.
Isomorphic is already running 18 to 19 live drug programs, cardiovascular disease, cancer, immunology in partnership with Eli Lilly, Novartis, and Johnson and Johnson.
The first human clinical trial of a fully AI-designed drug is expected by the end of 2026.
If that trial succeeds, it will be the first time in history that a drug put into a human body was designed not by a team of chemists working for a decade but by an AI working for months.
Hassabis's long-term vision is even more direct, one day you describe a disease, click a button, and a drug blueprint comes out the other side.
AI will solve almost all diseases within 10 years.